{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:13:32Z","timestamp":1789791212794,"version":"4.0.1"},"reference-count":51,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T00:00:00Z","timestamp":1673740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Endogenous nitric oxide (NO)-dependent vascular relaxation plays a leading role in the homeostasis of the cardiovascular, pulmonary, and vascular systems and organs, such as the kidneys, brain, and liver. The mechanism of the intracellular action of NO in blood vessels involves the stimulation of the activity of the soluble cytosolic form of guanylyl cyclase (soluble guanylyl cyclase, sGC), increasing the level of cyclic 3\u2032-5\u2032\u2014guanosine monophosphate (cGMP) in smooth muscle and subsequent vasodilation. In recent years, a new group of drugs, soluble guanylyl cyclase stimulators, has found its way into clinical practice. Based on the CHEST-1 and PATENT-1 trials, riociguat was introduced into clinical practice for treating chronic thromboembolic pulmonary hypertension (CTEPH). In January 2021, the FDA approved the use of another drug, vericiguat, for the treatment of heart failure.<\/jats:p>","DOI":"10.3390\/molecules28020861","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T04:57:19Z","timestamp":1673845039000},"page":"861","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Soluble Guanylyl Cyclase Activators\u2014Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6669-5931","authenticated-orcid":false,"given":"Grzegorz","family":"Grze\u015bk","sequence":"first","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Colle-gium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Ujejskiego St., 85-168 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Witczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Byd-goszcz, Nicolaus Copernicus University in Toru\u0144, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"W\u0119glarz","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Colle-gium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Ujejskiego St., 85-168 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7731-6367","authenticated-orcid":false,"given":"\u0141ukasz","family":"Wo\u0142owiec","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences, Ludwik Rydygier Colle-gium Medicum in Bydgoszcz, Nicolaus Copernicus University, 75 Ujejskiego St., 85-168 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4521-8065","authenticated-orcid":false,"given":"Jacek","family":"Nowaczyk","sequence":"additional","affiliation":[{"name":"Physical Chemistry and Chemistry of Polymers, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarina St., 87-100 Toru\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Grze\u015bk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hematology and Oncology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 9 Sk\u0142odowskiej-Curie St., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-2369","authenticated-orcid":false,"given":"Alicja","family":"Nowaczyk","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Byd-goszcz, Nicolaus Copernicus University in Toru\u0144, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2045894020977300","DOI":"10.1177\/2045894020977300","article-title":"Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Identification of the most accurate estimates from a systematic literature review","volume":"11","author":"Leber","year":"2021","journal-title":"Pulm Circ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nowaczyk, A., Kowalska, M., Nowaczyk, J., and Grze\u015bk, G. (2021). Carbon Monoxide and Nitric Oxide as the Examples of the Youngest Class of Transmitters. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116029"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-540-68964-5_2","article-title":"Biochemistry of soluble guanylate cyclase","volume":"191","author":"Derbyshire","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Grze\u015bk, G., and Nowaczyk, A. (2021). Current modulation of guanylate cyclase pathway activity-mechanism and clinical implications. Molecules, 26.","DOI":"10.3390\/molecules26113418"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_7","first-page":"615","article-title":"Vericiguat jako stymulator cyklazy guanylanowej elementem innowacyjnej terapii niewydolno\u015bci serca","volume":"77","author":"Kowalkowska","year":"2021","journal-title":"Farm. Pol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sandner, P., Follmann, M., Becker-Pelster, E., Hahn, M.G., Meier, C., Freitas, C., Roessig, L., and Stasch, J.P. (Br. J. Pharmacol., 2021). Soluble GC stimulators and activators: Past, present and future, Br. J. Pharmacol., ahead of print.","DOI":"10.1111\/bph.15698"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"ref_11","unstructured":"Schmidt, H.H.H.W., Ghezzi, P., and Cuadrado, A. (2019). Correction to: Soluble guanylate cyclase stimulators and activators. Reactive Oxygen Species. Handbook of Experimental Pharmacology, vol 264, Springer."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2021.1866538","article-title":"Soluble guanylate cyclase stimulators and their potential use: A patent review","volume":"31","author":"Sandner","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1039\/D1RA08120A","article-title":"Synthetic strategy and structure\u2013activity relationship (SAR) studies of 3-(5\u2032-hydroxymethyl-2\u2032-furyl)-1-benzyl indazole (YC-1, Lificiguat): A review","volume":"12","author":"Yu","year":"2022","journal-title":"RSC Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1107\/S2052520617006011","article-title":"Comparison of the crystal structures and thermochemistry of a novel soluble guanylate cyclase stimulator riociguat and its solvates","volume":"73","author":"Zhou","year":"2017","journal-title":"Acta Cryst. B Struct. Sci. Cryst. Eng. Mater."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107578","DOI":"10.1016\/j.cclet.2022.06.001","article-title":"Fluorine-containing drugs approved by the FDA in 2021","volume":"34","author":"He","year":"2022","journal-title":"Chin. Chem. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1800094","DOI":"10.1002\/adtp.201800094","article-title":"Investigational pharmacological treatments for vascular calcification","volume":"2","author":"Schantl","year":"2019","journal-title":"Adv. Therap."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bragina, M.E., Daina, A., Perez, M.A.S., Michielin, O., and Zoete, V. (2022). The Swiss Similarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020811"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drudis.2010.11.002","article-title":"The graphical representation of ADME-related molecule properties for medicinal chemists","volume":"16","author":"Ritchie","year":"2011","journal-title":"Drug. Discov. Today"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Grze\u015bk, G., Rogowicz, D., Wo\u0142owiec, \u0141., Ratajczak, A., Gilewski, W., Chudzi\u0144ska, M., Sinkiewicz, A., and Banach, J. (2021). The clinical significance of drug-food interactions of direct oral anticoagulants. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168531"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"(2016). The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J., 37, 67\u2013119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1183\/09059180.00011112","article-title":"Soluble guanylate cyclase stimulation: An emerging option in pulmonary hypertension therapy","volume":"18","author":"Ghofrani","year":"2009","journal-title":"Eur. Respir. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00000542-199002000-00005","article-title":"Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: Effects on pulmonary capillary pressure and ventilation-perfusion distributions","volume":"72","author":"Radermacher","year":"1990","journal-title":"Anesthesiology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMc051946","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/FJC.0000000000000806","article-title":"Thrombocytopenia During Prostacyclin Analogue Therapies of Pulmonary Arterial Hypertension\u2014Possible Pathomechanisms and Implications","volume":"75","author":"Karasek","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00039808","article-title":"First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension","volume":"33","author":"Grimminger","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1183\/09031936.00182909","article-title":"On behalf of the study investigators, Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study","volume":"36","author":"Ghofrani","year":"2010","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"PATENT-1 Study Group Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: A long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: A blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Scalise","year":"2015","journal-title":"Eur. Resp. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"CHEST-1 Study GroupA Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. (CHEST-1)","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1183\/09031936.00087114","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: A long-term extension study (CHEST-2)","volume":"45","author":"Simonneau","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijcard.2015.05.105","article-title":"Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"195","author":"Marra","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated with Diastolic Heart Failure (DILATE-1)","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/680214","article-title":"Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease","volume":"5","author":"Ghofrani","year":"2015","journal-title":"Pulm. Circ."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1183\/09031936.00213911","article-title":"Riociguat for interstitial lung disease and pulmonary hypertension: A pilot trial","volume":"41","author":"Hoeper","year":"2013","journal-title":"Eur. Resp. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"SOCRATES-REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jchf.2020.09.001","article-title":"Vericiguat in Heart Failure With Reduced Ejection Fraction With High Natriuretic Peptides: A Case of Too Little, Too Late?","volume":"8","author":"Cunningham","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: Results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. The VITALITY-HFpEF Randomized Clinical Trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1625290","DOI":"10.1155\/2022\/1625290","article-title":"Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-\u03baB Pathways","volume":"2022","author":"Sun","year":"2022","journal-title":"Mediat. Inflamm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1001\/jama.2020.16641","article-title":"Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction The CAPACITY HFpEF Randomized Clinical Trial","volume":"324","author":"Udelson","year":"2020","journal-title":"JAMA"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/2\/861\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:06:33Z","timestamp":1760119593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/28\/2\/861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,15]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["molecules28020861"],"URL":"https:\/\/doi.org\/10.3390\/molecules28020861","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,15]]}}}